Sonnet Accounts Payable from 2010 to 2024
SONN Stock | USD 2.98 0.09 3.11% |
Accounts Payable | First Reported 2006-06-30 | Previous Quarter 1.8 M | Current Value 1.9 M | Quarterly Volatility 47.8 M |
Check Sonnet Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sonnet Biotherapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 2.4 M or Selling General Administrative of 2.4 M, as well as many indicators such as Price To Sales Ratio of 1.12, Dividend Yield of 0.0 or PTB Ratio of 5.12. Sonnet financial statements analysis is a perfect complement when working with Sonnet Biotherapeutics Valuation or Volatility modules.
Sonnet | Accounts Payable |
Latest Sonnet Biotherapeutics' Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Sonnet Biotherapeutics Holdings over the last few years. An accounting item on the balance sheet that represents Sonnet Biotherapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Sonnet Biotherapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Sonnet Biotherapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sonnet Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable | 10 Years Trend |
|
Accounts Payable |
Timeline |
Sonnet Accounts Payable Regression Statistics
Arithmetic Mean | 3,182,444 | |
Geometric Mean | 2,000,844 | |
Coefficient Of Variation | 66.66 | |
Mean Deviation | 1,704,680 | |
Median | 2,381,273 | |
Standard Deviation | 2,121,430 | |
Sample Variance | 4.5T | |
Range | 6.9M | |
R-Value | (0.03) | |
Mean Square Error | 4.8T | |
R-Squared | 0.0009 | |
Significance | 0.91 | |
Slope | (14,563) | |
Total Sum of Squares | 63T |
Sonnet Accounts Payable History
About Sonnet Biotherapeutics Financial Statements
Sonnet Biotherapeutics investors utilize fundamental indicators, such as Accounts Payable, to predict how Sonnet Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last Reported | Projected for Next Year | ||
Accounts Payable | 2.4 M | 2.3 M |
Check out the analysis of Sonnet Biotherapeutics Correlation against competitors. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.96) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.50) | Return On Assets (0.97) | Return On Equity (2.65) |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.